Business Wire

THALES

1.7.2021 09:02:13 CEST | Business Wire | Press release

Share
High-tech Solutions From Thales Optimise the Air Passenger Experience From Home to the Airport

As airports prepare for the busy summer period, they are facing a new set of challenges; dealing with the public health crisis and complying with new regulations on freedom of movement within the Schengen Area. Thales technologies enable airport operators, airlines and border officials to enhance the travel experience and increase security at four main points around the airport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005080/en/

Secure check-in
Passengers can check in remotely from any location (home, hotel, etc.) using their airline's mobile app. The identity of each individual can then be instantly verified with face recognition software, using a combination of a selfie taken by the passenger, liveness detection and a document authenticity check. The face recognition solution checks approximately 40 points on the passenger's face and issues an alert if there is any doubt about their identity.

Based on this identity verification and facial biometrics, a temporary digital token is then created for each passenger. The passenger's face then identifies them at check-in, bag drop-off, security, passport control and the boarding gate, removing the need to show a ticket and ID card at each checkpoint. The system analyses the facial features of an individual in real time, even when they are wearing a surgical mask, and matches it to the corresponding digital identity in the system. No personal data or photos are stored; an encrypted code created during check-in is the only reference the system requires.

Passengers are identified at the boarding gate in less than a second
During boarding, passengers are instantly identified by face recognition, without needing to remove their masks or show their boarding passes. In some cases, ground staff may be required to ask a passenger to show their health pass, which can be stored in a digital ID wallet on their smartphone, to prove their vaccination status, PCR test results, etc. This mobile ID wallet protects the passengers' personal data and certifies the authenticity, validity and integrity of the health data. Health passes can also be authenticated when passengers check in before arriving at the airport.

This biometric solution for boarding gates reduces boarding times by one-third. The system erases the temporary token once the aircraft has taken off.

Smart airport operations to optimise the flow of passengers
High-tech solutions from Thales also help to manage airport operations at numerous destinations. The Group provides airport operators with smart solutions and decision support tools that help them optimise and control passenger flows inside the terminal (from the entrance to the boarding and/or arrival gate). Using high-performance algorithms, these tools and solutions enable airport operators and other stakeholders to model flight arrivals and departures as well as other airport data and run simulations. Based on those simulations, they can anticipate possible travel disruptions (late or cancelled flights) and adjust resource availability on the ground to improve the passenger experience and reduce waiting times.

New border kiosks to simplify passport control for non-European nationals
Under the new requirements for member states of the Schengen Area, non-European nationals arriving in France will soon be able to use Thales's self-service border kiosks to pre-register their identity, including their biometric data (fingerprint and facial biometrics), in less than one minute.

Pre-registration offers time savings of 30% at passport control. The system software is optimised for ultra-rapid document authentication and fraud detection. Several ports of entry (airports, ports, train stations) are due to be equipped with Thales’ border kiosks between now and May 2022.

"For several decades, Thales has been helping to manage and secure sensitive infrastructure like stations, sports arenas and other major cultural venues. With its expertise in new technologies such as AI, deep learning and biometrics, boosted by the acquisition of Gemalto in 2019, Thales is in a position to provide airports and their ecosystems with new ways to increase operational efficiency, better protect the health and safety of passengers and enhance the travel experience. Thales technologies offer secure solutions that simplify the passenger experience while guaranteeing that personal data is protected and managed with complete transparency." Philippe Keryer, Executive Vice President, Strategy, Research and Technology, Thales

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defence, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.

PLEASE VISIT

Thales Group
Market page

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C

Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release

The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag

Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda

Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release

Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm

No-Loss Trading Platform UpsideOnly Surpasses 100,000 Users Within Weeks of Launch6.7.2026 14:48:00 CEST | Press release

Rapid growth shows strong demand for a new trading model where users can make market predictions without risking their own capital Perpetuals.com Ltd (Nasdaq: PDC), today announced that UpsideOnly, its risk-free trading and market prediction platform, has seen a surge in new user sign-ups, surpassing the important milestone of 100,000 traders within weeks of its launch on May 19. UpsideOnly lets users make predictions about where global equity, commodity, forex, and crypto markets are heading without ever placing a real trade themselves. Perpetuals uses its own capital to trade on the strongest signals identified by its proprietary AI. If those trades win, Perpetuals shares the profits with the users who helped generate the signal. If the trade doesn’t make money, users lose nothing. Reaching 100,000 users so quickly after launching is a reflection of the enormous demand for a platform that flips the traditional retail trading model on its head, with early platform data showing strong

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye